RxDoctor Payments Data

Silva Arslanian-Makaroun

Pittsburgh, PANPI 1649242033

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $89,418 of the $128,356 with a category attached, or 69.7%. 13 manufacturers reported payments, led by Novo Nordisk AS at 36.0% of the total. Reporting peaked in 2024 at $50,626 and has fallen 79.0% since, to $10,635 in 2025.

$128,356in general payments, 2019–2025

Across 67 payments — averaging $1915.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$46K
  • Eli Lilly$42K
  • Novo Nordisk$13K
  • Astrazeneca UK Limited$12K
  • Sanofi-aventis U.S. LLC$8K
  • Boehringer Ingelheim International GmbH$7K
  • plus $1K from 7 others
$1,261,795in research payments, 2019–2025

Across 5,041 payments — averaging $250.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$1.1M
  • Eli Lilly$183K
  • Astrazeneca UK Limited$4K

What the payments were for

  • Consulting fees$89,41870%
  • Speaking & faculty fees$8,9177%
  • Travel & lodging$28,26822%
  • Food & beverage$1,6561%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →